GSK (LON:GSK) Given Underweight Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their underweight rating on shares of GSK (LON:GSK) in a research note published on Wednesday,Digital Look reports.

Other analysts have also recently issued research reports about the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research report on Wednesday. Berenberg Bank lifted their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research report on Monday, November 24th. Finally, Shore Capital reiterated a “buy” rating on shares of GSK in a report on Thursday. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of GBX 1,762.

GSK Stock Up 0.1%

Shares of GSK stock traded up GBX 1.25 during trading on Wednesday, hitting GBX 1,902.75. 7,630,360 shares of the stock traded hands, compared to its average volume of 6,804,678. The stock has a market cap of £76.76 billion, a P/E ratio of 14.31, a PEG ratio of 1.24 and a beta of 0.31. The company has a fifty day moving average price of GBX 1,805.21 and a two-hundred day moving average price of GBX 1,595.16. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 1,909.73.

GSK (LON:GSK) last posted its earnings results on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insider Transactions at GSK

In related news, insider Jonathan Symonds purchased 1,650 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were acquired at an average cost of GBX 1,810 per share, with a total value of £29,865. Also, insider Wendy Becker bought 441 shares of the business’s stock in a transaction on Friday, December 19th. The shares were acquired at an average price of GBX 1,809 per share, for a total transaction of £7,977.69. 0.20% of the stock is owned by corporate insiders.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK’s bepirovirsen met key goals in chronic hepatitis B studies, showing promising antiviral results — a material pipeline win that could unlock a new treatment franchise if advanced. Read More.
• Positive Sentiment: The European Commission approved a Shingrix prefilled syringe presentation, improving ease-of-use and commercial potential in Europe for an established vaccine franchise. Read More.
• Positive Sentiment: Japan’s MHLW approved Exdensur, expanding GSK’s marketed portfolio in a major market — a near-term revenue and access positive. Read More.
• Positive Sentiment: Jefferies reaffirmed a “buy” rating and set a GBX 2,100 price target — a bullish analyst view implying upside from current levels. Read More.
• Positive Sentiment: Shore Capital also reaffirmed a “buy” rating, adding to the supportive broker commentary. Read More.
• Neutral Sentiment: Market commentary includes a valuation check after strong one‑year shareholder returns — useful context for investors assessing whether recent gains are sustainable. Read More.
• Neutral Sentiment: Non-core real-estate activity: a vacant former GSK building at the Navy Yard sold for $52M — immaterial to core pharma ops but worth noting for local asset disposition. Read More.
• Negative Sentiment: JPMorgan reaffirmed an “underweight” rating, signaling caution from a major bank that may pressure investor sentiment. Read More.
• Negative Sentiment: Barclays downgraded GSK, another negative broker move that increases selling pressure despite the clinical/regulatory positives. Read More.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.